The Rapid Intervention with Glyceryl Trinitrate in Hypertensive Stroke Trial-2 (RIGHT-2) is a clinical trial assessing the safety and efficacy of transdermal glyceryl trinitrate (GTN) patches vs. sham patch for patients suffering acute stroke when administered ultra-acutely by paramedics in the pre-hospital setting.
It is a UK-based, multicentre prospective randomised single-blind, blinded-endpoint parallel group trial. RIGHT-2 recruited 1,149 patients across 8 UK ambulance trusts and collaborated with 54 stroke units to determine whether GTN improves outcome in patients with ultra-acute stroke.
Seeking emergency medical care in the community, time-critical patients presenting with stroke symptoms to paramedics are now routinely conveyed to specialist hyper-acute stroke centres. Paramedics, at the forefront of pre-hospital emergency care, were well placed to begin this ultra-acute intervention to this high-risk patient group.
RIGHT-2 worked with stroke centres across the UK who received emergency ambulance admissions to continue the treatment with GTN patch or sham patch for three further days. The patient outcome will be measured using the modified Rankin Scale to determine death, the level of dependence or independence at 90 and 365 days post stroke.
Go to http://right-2.ac.uk/live/ for the live database. You will need to use the User ID and PIN provided in the activation email. You should have set your own password already as part of the activation process.
If you have forgotten your password, there is a reset facility at the above link.
The trial is funded by the British Heart Foundation. Recruitment was from September 2015 to May 2018. Telephone follow-ups will continue until May 2019.
NIHR CRN portfolio (link)
ISRCTN registration (link)
Good Morning Britain - The 39p heart patch that could save lives (link), 05/05/2017
The Guardian - Skin patch costing 39p could save lives of stroke victims, researchers say (link), 05/05/2017
The Times - Patch could halve stroke deaths for 39p per patient (link), 05/05/2017
The Express - Stroke survival: Skin patch that costs just 39p 'could save THOUSANDS of lives' (link), 05/05/2017
The Express - Stroke news: A 39p patch could DOUBLE your chances of SURVIVAL (link), 05/05/2017
Daily Mail - 39p skin patch 'can halve the risk of death after a stroke' by lowering blood pressure and relaxing veins and arteries to improve circulation (link), 05/05/2017
The Sun - GAME CHANGER Tens of thousands of stroke victims’ lives could be saved by a 39p skin patch (link), 05/05/2017
Daily Record - The 39p skin patch that could save your life (link), 05/05/2017
Evening Standard - Skin patches costing only 39p 'could cut stroke deaths by half' (link), 05/05/2017
Huffington Post UK - 39p Drug Skin Patch Could ‘Dramatically’ Improve Stroke Survival (link), 05/05/2017
ITV News - 39p patch could 'save lives' (link), 05/05/2017
British Heart Foundation - Medicine patch could revolutionise stroke treatment (link), 05/05/2017
Notts TV - Stroke patch invented in Nottingham could double chances of survival (link), 08/05/2017
East Midlands Ambulance Service - EMAS leads the way on treatment for stroke patients (link)
Patch demonstration (.mxf), 27/05/2015
Interview with Professor Philip Bath and Adam Hayes, stroke survivor (.mxf), 27/05/2015
To view .mxf files, you may need to download VLC for free.
Early use of patch 'could help treat strokes' (link), 27/05/2015
Andy Whittaker's Breakfast Show (link) on BBC Radio Nottingham, 27/05/2015 (recording by Trials Team)
Improving Stroke Outcomes (link), 10/09/2015
For the following video you will need to sign up here: this is free but only registered health professionals (who input the required registration numbers) will be able to view this video.
ENOS trial (link), 10/09/2015: RIGHT-2 is mentioned towards the end.
Determining the feasibility of ambulance-based randomised controlled trials in patients with ultra-acute stroke: study protocol for RIGHT (pdf), 21 September 2012
Feasibility of an ambulance-based trial, and safety of glyceryl trinitrate in ultra-acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT) (pdf); published in Stroke, 7 June 2013
Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the ENOS trial (pdf), November 2006
Go to http://right-2.ac.uk/demo/ if you wish to practice data entry etc.
Please note that data entered into this database is not entered into the live trial database and does not contribute to trial data. This database does, of course, replicate and demonstrate the same functions as the main trial database.
You will need the following credentials to log in:
Trial Steering Committee:
Craig Anderson (Sydney, Australia), Eivind Berge (Oslo, Norway), Peter Rothwell (Oxford, UK), Steve Phillips (Halifax, Canada), Else Sandset (Oslo, Norway), Nerses Sanossian (Los Angeles, USA), Jeff Saver (Los Angeles, USA)
Trial Management Committee (Nottingham):
Philip Bath (Chair), Diane Havard (Trial Manager), Harriet Howard (Trial Coordinator), Mark Dixon (National Paramedic), Polly Scutt (Statistician), Jason Appleton (Medic), Nadia Frowd (Outcome Coordinator), Robert Gray (Outcome Coordinator), Christopher Lysons (Outcome Coordinator), Lee Haywood (Programming), Patricia Robinson (Secretary)
Independent Data Monitoring Committee:
Peter Sandercock (Chair; Edinburgh, UK): Kjell Asplund (Umeå, Sweden), Colin Baigent (Oxford, UK)
Independent Events (SAE) Adjudicator:
Sandeep Ankolekar (Birmingham, UK), Marc Randall (Leeds, UK)
Joanna Wardlaw (Chair; Edinburgh, UK): Lesley Cala (Perth, Australia), Grant Mair (Edinburgh, UK)
Eleni Sakka (Edinburgh, UK)
Website/database (Nottingham, UK): Lee Haywood
Imaging (Edinburgh, UK): David Buchanan, Jeb Palmer
For information about how we store, retain, share and manage your personal data for RIGHT-2, please refer to our website privacy notice document.
For information about how we use your personal data for RIGHT-2 in accordance with UK data protection laws, please refer to our data protection supplementary information document.
Written by Philip Bath, last updated by Lee Haywood, 19 March 2019